Sildenafil for the treatment of pulmonary hypertension in children

Beghetti, Maurice; Wacker Bou Puigdesabregas, Julie Caroline; Merali, Sausan

doi:10.1586/14779072.2014.958077

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Sildenafil for the treatment of pulmonary hypertension in children
Authors		Beghetti, Maurice Wacker Bou Puigdesabregas, Julie Caroline Merali, Sausan
Published in		Expert Review of Cardiovascular Therapy. 2014, vol. 12, no. 10, p. 1157-84
Abstract		Pulmonary hypertension, including pulmonary arterial hypertension (PAH), is a serious disease in children, but few clinical studies have been conducted to evaluate treatment regimens in this population. Currently, treatment of children with PAH is mostly based on clinical studies conducted in adults and a few dedicated pediatric studies. Sildenafil, a phosphodiesterase type 5 inhibitor, has an established efficacy and safety profile for the treatment of adults with PAH. In May 2011, sildenafil received approval for the treatment of pediatric patients aged 1-17 years in the EU; however, pediatric use is not approved in the USA. This systematic literature review summarizes the clinical data available on the use of sildenafil to treat children with PAH and pulmonary hypertension.
Identifiers		DOI: 10.1586/14779072.2014.958077 PMID: 25223406
Full text		Article (Published version) (616 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique
Research group		L'hypertension pulmonaire (pédiatrie) (228)
Citation (ISO format)		BEGHETTI, Maurice, WACKER BOU PUIGDESABREGAS, Julie Caroline, MERALI, Sausan. Sildenafil for the treatment of pulmonary hypertension in children. In: Expert Review of Cardiovascular Therapy, 2014, vol. 12, n° 10, p. 1157-84. doi: 10.1586/14779072.2014.958077 https://archive-ouverte.unige.ch/unige:72698